Literature DB >> 22819796

Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan.

Chih-Cheng Lai1, Chen-Chen Chu, Cheng-Yi Wang, Hsih-Yeh Tsai, Aristine Cheng, Yi-Chieh Lee, Yu-Tsung Huang, Chun-Hsing Liao, Po-Ren Hsueh.   

Abstract

This study investigated the correlations between consumption of antifungal agents and species distribution in candidaemia. The incidence of patients with community-acquired candidaemia (CAC) (per 1000 admissions) and healthcare-associated candidaemia (HCAC) (per 1000 admissions) as well as data on annual consumption [defined daily doses (DDD)/1000 patient-days] of various antifungal agents at a medical centre in Taiwan from 2000 to 2010 were evaluated. A total of 2682 episodes of candidaemia were identified, including 2468 HCAC (92.0%) and 214 CAC (8.0%). The most prevalent species was Candida albicans (53.3%), followed by Candida tropicalis (20.5%), Candida glabrata (15.4%), Candida parapsilosis (14.1%), Candida guilliermondii (1.7%) and Candida krusei (1.5%). The overall incidence of candidaemia remained stable, whereas that of candidaemia due to C. parapsilosis and C. guilliermondii decreased significantly with time. Significant negative correlations were found between the use of echinocandins and voriconazole and the incidence of C. parapsilosis candidaemia and between the use of caspofungin and the incidence of C. guilliermondii candidaemia. In contrast, there were significant positive correlations between the use of echinocandins and the incidence of C. tropicalis candidaemia, the use of azoles and the incidence of C. glabrata and non-albicans Candida candidaemia, and the use of itraconazole and the incidence of C. parapsilosis and C. guilliermondii candidaemia. Increased use of fluconazole was associated with an increased incidence of HCAC due to non-albicans Candida spp. In conclusion, the impact of consumption of antifungal agents on the incidence of candidaemia caused by different Candida spp. varies and warrants further studies to confirm these findings.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819796     DOI: 10.1016/j.ijantimicag.2012.05.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany.

Authors:  Barbara N Gross; Michaela Steib-Bauert; Winfried V Kern; Holger Knoth; Johannes P Borde; Sabine Krebs; Martin J Hug; Ulrich Rothe; Ludwig Maier; Katja de With
Journal:  Infection       Date:  2015-02-17       Impact factor: 3.553

3.  Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Authors:  Brunella Posteraro; Teresa Spanu; Barbara Fiori; Flavio De Maio; Elena De Carolis; Alessia Giaquinto; Valentina Prete; Giulia De Angelis; Riccardo Torelli; Tiziana D'Inzeo; Antonietta Vella; Alessio De Luca; Mario Tumbarello; Walter Ricciardi; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

4.  Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).

Authors:  Michael A Pfaller; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  J Antibiot (Tokyo)       Date:  2015-04-22       Impact factor: 2.649

5.  Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

Authors:  A Fekkar; E Dannaoui; I Meyer; S Imbert; J Y Brossas; M Uzunov; G Mellon; S Nguyen; E Guiller; E Caumes; V Leblond; D Mazier; M H Fievet; A Datry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

6.  Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai.

Authors:  Zhi-Tao Yang; Lin Wu; Xiao-Ying Liu; Min Zhou; Jie Li; Jia-Yin Wu; Yong Cai; En-Qiang Mao; Er-Zhen Chen; Olivier Lortholary
Journal:  BMC Infect Dis       Date:  2014-05-06       Impact factor: 3.090

7.  Usefulness of defined daily dose and days of therapy in pediatrics and obstetrics-gynecology: a comparative analysis of antifungal drugs (2000-2001, 2005-2006, and 2010-2011).

Authors:  Justine Guillot; Denis Lebel; Hélène Roy; Philippe Ovetchkine; Jean-François Bussières
Journal:  J Pediatr Pharmacol Ther       Date:  2014-07

8.  Changing aetiology of healthcare-associated bloodstream infections at three medical centres in Taiwan, 2000-2011.

Authors:  C C Lai; Y H Chen; S H Lin; K P Chung; W H Sheng; W C Ko; P R Hsueh
Journal:  Epidemiol Infect       Date:  2014-10       Impact factor: 4.434

9.  Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.

Authors:  Eun Jeong Won; Jong Hee Shin; Min Ji Choi; Wee Gyo Lee; Yeon-Joon Park; Young Uh; Shine-Young Kim; Mi-Kyung Lee; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

10.  Epidemiology and prognostic factors of candidemia in cancer patients.

Authors:  Hung-Jen Tang; Wei-Lun Liu; Hsin-Lan Lin; Chih-Cheng Lai
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.